Friday | January 28th, 2022
Last Friday’s Career Connect Day presented by BioTalent Canada broke records; we had 841 registered attendees—way more than last year’s 696—making it the biggest STEM career event we’ve ever held and certainly the biggest in BC, if not Canada. We connected with 598 students from 57 academic institutions and 66 companies, all representing 19 countries around the world. A big thank you to our speakers, sponsors, and event supporters who made it happen, and thank you to you for attending!  

The feedback and connections from the event make me extremely proud that Life Sciences BC is here to support the life sciences sector in the province. Our next influx of talent I’m sure will give us more to celebrate in the near future. This week, the first COVID antiviral treatment pill from LSBC member and platinum sponsor, Pfizer arrives in BC. This week is also the one-year anniversary for Aurinia’s lupus treatment, Lupkynis gaining FDA approval; you can celebrate along with the Aurinia team here. Also, wishing LSBC member, ABOzymes success at the upcoming 2022 OBIO Investment Summit next month.  

In other celebrations, LSBC board member, Pieter Cullis and colleagues, Katalin Kariko and Drew Weissman have won the Vin Future Foundation’s first global Sci Tech award. The trio are recognized for their mRNA tech development that made the current COVID vaccines possible.  
Cullis’s fellow Order of Canada appointee, Peter Zandstra is featured in Stu McNish’s latest Conversations That Matter podcast.

Congratulations to the new Vancouver Magazine Power 50 list released this week; Pieter Cullis is celebrated in this list as a first timer along with the Honourable Ravi Kahlon, Minister for Jobs, Economic Development and Innovation who gave such a warm welcome to our delegates at Career Connect Day.

Acuitas Therapeutics welcomes former McCarthy-Tetrault partner, Miranda Lam as Chief Legal Officer, and Chinook Therapeutics has this warm video welcome to Charlotte Jones-Burton who joins the Leadership Team.
I’d like to share a couple of calls for application with you this week. Takeda Canada is looking for innovative solutions within the fields of early diagnosis or integrated and personalized care, applicable to the therapeutic areas of inflammatory bowel disease (ulcerative colitis or crohn's disease) or rare genetic diseases. Application details here. (deadline February 6). The Discovery Parks call for applicants deadline of February 4 is also fast approaching.

We also have a call out, for applications to Invest in the West presented by Amplitude Ventures. Details are on our website and the deadline is February 1.

Business in Vancouver’s Tyler Orton gave us an excellent summary of our Career Connect Day keynote and panel sessions, highlighting the need for skilled talent and bringing attention to the looming shortage in our sector. Presenting sponsor, BioTalent Canada unveiled their latest labour market study at the event and this week, announced a wage subsidy program for attracting international experts to the sector.

Orton also notes another issue – diversity; representation is key in attracting skilled talent and also in healthcare research for continuing life sciences success. At our Access to Innovation summit, February 16 and 17 you can listen as industry thought leaders discuss the latest action on encouraging diversity in the clinical trials.

I also encourage you to register for the women in biotech panel hosted by Aspect BioSystems on February 11th to celebrate International Day of Women and Girls in STEM.

Wendy and the LSBC Team
Please visit our Flood and Landslide Relief Program page to learn about this and other initiatives
BioTalent Canada announced the launch of a new program: the Skilled Newcomer Internships for the Bio-economy program that will provide employers with funds to integrate skilled newcomers and internationally educated professionals (IEPs) into the Canadian bio-economy....Read More
Miranda Lam has joined Acuitas Therapeutics as Chief Legal Officer & Sr.
Director, Business Development, Acuitas President and CEO, Dr. Thomas Madden, announced
Merck announced that the U.S. FDA has issued a Complete Response Letter regarding Merck’s New Drug Application for gefapixant, the investigational, non-narcotic, orally administered selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough or unexplained chronic cough in adults...Read More
Algernon Pharmaceuticals Inc. disclosed that as part of its intellectual property patent applications filed in early 2021 for AP-188, the Company included novel salt forms of DMT...Read More
Aequus Pharmaceuticals Inc. announced that it has agreed to an extension of terms for its promotional service agreement with Sandoz on Tacrolimus immediate-release to December 31st, 2022... Read More
Acuitas Therapeutics has entered into a new, long-term partnership with
Science World, President & CEO Dr. Thomas Madden has announced. The integrated engagement between the two organizations concentrates on human health and enrichment education and is founded on a mutual alignment in... Read More
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib in myelofibrosis patients who are symptomatic and anemic... Read More
Michael Watson, a partner in Gowling WLG’s Toronto office, was recently presented with the prestigious Court of Appeal Medallion for his legal and administrative efforts throughout the COVID-19 pandemic... Read More
Roche announced that the U.S. Food and Drug Administration has granted priority review of a supplemental new drug application for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy ... Read More
AbbVie announced the U.S. Food and Drug Administration has approved SKYRIZI® for the treatment of adults with active psoriatic arthritis, a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.1,4-7... Read More
Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon... Read More
Takeda Canada Inc. announced the launch of the Takeda Canada Innovation Challenge, an initiative that aims to discover new and breakthrough digital technologies and artificial intelligence solutions that support enhanced patient care... Read More
Numinus Wellness Inc., a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its research facility, Numinus Bioscience, has been included on Health Canada’s list of federally licensed psilocybin producers... Read More
If your organization is looking for talented grad students for positions starting in January, May or September 2022, please consider the MedTech Talent Accelerator. The accelerator is a training program designed to launch the next generation of industry-ready talent ... READ MORE
Nine new coronaviruses have been discovered by a research team led by a former University of British Columbia (UBC) postdoctoral fellow in medical genetics. Dr. Artem Babaian and his team at the Serratus Project made the discovery after re-analyzing all publicly available RNA sequencing data worldwide... READ MORE
Our 2022 funding competition lineup provides opportunities for BC health researchers across all regions of the province. These competitions reflect rigorous program evaluation; collection of robust data on equity, diversity and inclusion; and direct input from BC’s health research community... READ MORE
The IHE Life Sciences Market Access Program supports Alberta and British Columbia-based life sciences companies with promising, market-ready healthcare technology that are currently seeking market access in Canada or beyond... READ MORE
Canada Health Infoway has put together an AI toolkit to help health care organizations across Canada understand what is required to embark on an AI implementation journey. The toolkit provides both policy discussion and operational guidance... READ MORE
LSBC in The News
“The pipeline for talent is running low,” Rob Henderson, CEO of BioTalent Canada, stated bluntly during a Friday panel focused on B.C.’s life sciences sector ... READ MORE
Grantek is a system integrator and solution provider with a specialization in Smart Manufacturing solutions, Manufacturing Automation solutions, Industrial IT/Cybersecurity solutions and Manufacturing Consulting services. Grantek's 200+ employees automate Pharmaceutical / Life Science and Food & Beverage manufacturing operations, including integration with business systems for seamless solutions.

Visit Website
Aspect Biosystems is a biotechnology company creating bioprinted therapeutics as medicines of the future. Aspect is applying its microfluidic 3D bioprinting technology internally to develop these advanced cell therapies and partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine.

Quality Control Manager, Microbiology and
Environmental Monitoring

STEMCELL Technologies is seeking a Quality Control Manager, Microbiology and Environmental Monitoring who will plan and lead the daily operations related to QC Microbiology testing to ensure products meet STEMCELL Quality Standards. 

Research Animal Technician

BRI Biopharmaceutical Research Inc. is seeking a Research Animal Technician who is responsible for performing skilled technical duties, animal handling, restraint and manipulations, (SQ. PO. IV. IP. Tumor volume measurements) and minor surgeries.

LSBC Job Board

Jobs posted to our Job Board automatically post out to all our social media accounts for wider sharing. Make sure you include your company name in the first line of your job ad for maximum exposure!

Post A Job on the LSBC Website!
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five reposts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact Peter McLoughlin -